Table 3

Effect of biologic therapy on rheumatoid arthritis progression

Variable

N

Pre biologic therapy

Rate (95% CI)

Post biologic therapy

Rate (95% CI)

Rate difference

Rate (95% CI)


HAQ (all)

4,911

0.032 (0.027, 0.036)

0.003 (0.000, 0.006)

-0.029 (-0.023, -0.034)

HAQ (on)

3,829

0.031 (0.026, 0.036)

-0.001 (-0.004, 0.002)

-0.033 (-0.026, -0.039)

HAQ (DC)

1,082

0.033 (0.021, 0.044)

0.013 (0.008, 0.017)

0.020 (0.007, 0.033)

PCS (all)

4,911

-0.353 (-0.432, -0.273)

0.179 (0.129, 0.229)

-0.532 (-0.634, -0.430)

PCS (on)

3,829

-0.348 (-0.436, -0.260)

0.261 (0.198, 0.323)

-0.608 (-0.725, -0.491)

PCS (DC)

1,082

-0.396 (-0.591, -0.201)

-0.003 (-0.082, 0.075)

-0.393 (-0.619, -0.166)

MCS (all)

4,911

-0.096 (-0.176, -0.016)

0.000 (-0.056, 0.057)

-0.096 (-0.197, 0.005)

MCS (on)

3,829

-0.124 (-0.211, -0.037)

0.052 (-0.012, 0.116)

-0.176 (-0.289, -0.063)

MCS (DC)

1,082

0.015 (-0.083, 0.212)

-0.117 (-0.226, -0.008)

0.132 (-0.104, 0.368)

EQ-5D (all)

3,997

-0.003 (-0.005, -0.000)

0.002 (0.001, 0.003)

-0.005 (-0.008, -0.002)

EQ-5D (on)

3,031

-0.003 (-0.006, 0.000)

0.003 (0.002, 0.004)

-0.006 (-0.009, -0.002)

EQ-5D (DC)

966

-0.001 (-0.007, 0.004)

-0.001 (-0.003, 0.002)

-0.001 (-0.007, 0.006)

All patients

Pre biologic therapy

Mean (95% CI)

Post biologic therapy

Mean (95% CI)

Cost difference

Mean (95% CI)


Total Costs

4,911

$8,454 (8,140, 8,769)

$24,369 (21,172, 24,565)

$15,914 (15,543, 16,285)

Drug Costs

4,911

$4,681 (4,401, 4,961)

$20,401 (20,226, 20,576)

$15,720 (15,390, 16,051)

Variable

N

Estimated scores

Time = -10 years

Mean (95% CI)

Actual scores

Time = 0 years

Mean (95% CI)

Estimated scores

Time = +10 years

Mean (95% CI)


HAQ

4,911

1.02 (0.99, 1.05)

1.13 (1.11, 1.15)

1.24 (1.21, 1.27)

PCS

4,911

35.2 (34.7, 35.6)

35.4 (35.1, 25.7)

35.7 (35.2, 36.1)

MCS

4,911

50.2 (49.8, 50.7)

49.8 (49.5, 50.1)

49.3 (48.9, 49.8)

EQ-5D

3,997

0.721 (0.709, 0.733)

0.730 (0.724, 0.736)

0.740 (0.730, 0.749)


Effect of biologic therapy on annual rates of progression of disability, loss of health status, and costs in patients prior to and after the start of biologic therapy in RA.

All, all patients; on, on biologics at study close; DC, discontinued biologic before study close.

Positive rates indicate worsening HAQ disability. Negative rates indicate worsening health status for MCS, PCS, and EQ-5D. A negative rate difference indicates improvement. Times are relative to biologic therapy initiation.

HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.

Wolfe and Michaud Arthritis Research & Therapy 2010 12:R35   doi:10.1186/ar2944

Open Data